I+Med
- Company typePrivate
- Founded2014
- HeadquartersÁlava, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
I+Med firmographics
Firmographics- Name
- I+Med
- Legal name
- I+MED, S.COOP.
- Website
- https://imasmed.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
I+Med industry classification
Industry- Product category
- Pharmaceutical Contract Development & Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where I+Med is headquartered
LocationHeadquarters
- HQ city
- Álava
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
I+Med business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Development & Manufacturing (CDMO): Fee-for-service contract development, manufacturing, technology transfer, clinical trials, and full commercialization support provided to pharmaceutical companies globally; project-based, bespoke engagements.
- Own Product Portfolio: Direct sales of proprietary medical products in five therapeutic areas: Traumatology, Aesthetics, Ophthalmology, Dermatology, and Veterinary (e.g., hyaluronic-acid based injectables, viscoelastics, eye drops).
- Custom R&D Services (I+D a la carta): Tailored R&D engagements where i+Med applies its ADAPTEK technology and nanohydrogel expertise to client-defined problems; project-based revenue.
- Technology Licensing / Co-development: Licensing of ADAPTEK technology platform and co-development partnerships (implied through references to technology transfer and collaboration agreements).
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
I+Med product offering
Product offeringCore offering
I+Med is a pharmaceutical contract development and manufacturing organization (CDMO) that helps pharmaceutical companies develop and commercialize drug-delivery innovations using its proprietary ADAPTEK controlled-release technology platform, which combines patented nanohydrogels, active coatings for biomedical implants, and nanocarriers for vehiculization of active ingredients. In parallel, the company manufactures and sells its own portfolio of medical devices across five therapeutic areas — Traumatology, Aesthetics (including hyaluronic-acid injectables), Ophthalmology (viscoelastics and eye drops), Dermatology, and Veterinary — and offers custom R&D services (I+D a la carta) to clients requiring tailored vehiculization and molecule-delivery solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Development & Manufacturing (CDMO) Services
Quantifiable outcome
- Pharmaceutical development experience across 9 therapeutic areas
- +1 more outcomes
Companies that use I+Med
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
I+Med technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
I+Med partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major, flagship and operational.
- Unikare Bioscience S.L.coreIdentified as a directly related company to I+MED, S.COOP.; data is shared with Unikare Bioscience S.L. as needed for the execution of contractual or commercial relationships with i+Med customers.
- UNLOOC (European project consortium)majorEuropean R&D consortium in which i+Med participates; next consortium meeting scheduled in Zaragoza (Oct 30, 2025). Used for collaborative development and visibility in European projects.
- Hazitek IDIMO project consortiummajorHazitek (Basque Government R&D support program) project developing new advanced medical devices for the control and monitoring of immune response and infections (announced Mar 25, 2026).
- Plan de Industria Euskadi 2030 - 'Smart Hydrogels' consortiumflagshipTransformational project within the Basque Government's Plan de Industria Euskadi 2030, led by i+Med; focuses on 'Smart Hydrogels' (announced Mar 31, 2026).
- Labor, accounting and tax advisorsoperationalExternal advisors handling accounting, billing, personnel management, and other legal obligations of i+Med.
- Transport companiesoperationalLogistics partners responsible for shipping and delivery of i+Med's services and products.
- Service providers outside the EU (hosting, SaaS, IT, email marketing, etc.)operationalIT/hosting/SaaS/email-marketing/backup providers — some located outside the EU — used for ancillary services; international data transfers governed by standard contractual clauses.
- Factorial (HR/recruitment platform)operationalHosts i+Med's 'Work with Us' recruitment portal at i-med.factorial.es, used for candidate applications.
- Google Maps / Bing MapsoperationalMap/location services embedded to help users find the nearest i+Med facility.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
I+Med competitors and assessment
Company assessmentEmerging players
- Lifepharma (Lifecare Biomedical): Nordic biomedical company developing hydrogel and nano-based delivery systems for implantable medical devices and therapeutics; comparable to i+Med's hydrogel/nanohydrogel biomedical implant coating capabilities.
- Nanoform Finland: Public Finnish nanoformulation company commercializing proprietary nanoparticle technology to enhance drug bioavailability and delivery; directly comparable to i+Med's nanocarrier/nanohydrogel platform in applying nano-engineering to solve pharma drug-delivery challenges.
- Midatech Pharma: Clinical-stage specialty pharma developing nano-enabled drug delivery (gold-nanoparticle and polymer-based sustained-release platforms); comparable to i+Med's controlled-release nanohydrogel/nanocarrier technology and CDMO-style customization work for pharma partners.
Broad incumbents
- Recipharm: European-headquartered CDMO offering contract development and manufacturing of pharmaceuticals across multiple dosage forms and therapeutic areas; comparable to i+Med's enterprise B2B CDMO model and European geographic base, though operating at significantly larger scale.
- Evonik Health Care: Specialty chemicals/CDMO division offering advanced drug delivery including lipid nanoparticles and polymeric carriers for controlled release; closely comparable to i+Med's ADAPTEK nanohydrogel/nanocarrier technology platform, with similar transversal application across pharma customers.
- Catalent: One of the largest global CDMOs offering drug development, controlled-release formulation, and clinical/commercial manufacturing across many therapeutic areas; directly comparable to i+Med's CDMO and custom R&D offering but at vastly greater scale and with a much broader service portfolio.
- CordenPharma: Full-service CDMO providing contract development and manufacturing of APIs, drug products and packaging including specialty formulations; comparable to i+Med's CDMO + custom R&D model serving global pharma customers from European facilities.
- Lonza: Global CDMO providing development, manufacturing, and drug delivery technologies including nanoparticle formulations for pharma and biotech; comparable to i+Med in offering end-to-end pharma development services and advanced drug-delivery platforms, but at multi-billion-dollar scale and global footprint.
- Rentschler Biopharma: European biopharmaceutical CDMO offering process development and manufacturing of biologics and advanced therapies; comparable to i+Med's CDMO GTM motion of end-to-end partnership with pharma from R&D through clinical and commercial.
Regional players
- Biana Med (formerly Bioiberica): Spanish/Iberian life-science company with CDMO-like capabilities in biomaterials, hyaluronic acid products, and pharmaceutical ingredients across traumatology, aesthetics and ophthalmology; comparable to i+Med's own-product portfolio across the same specialty therapeutic areas and similar Iberian geographic footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
I+Med social profiles
Digital presenceI+Med compliance and trust
Trust signalCompliance3 records
I+Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
I+Med leadership team
Management profileNumber of profiles
I+Med subsidiaries and ownership
Company hierarchySubsidiaries1 record
I+Med funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
I+Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about I+Med
What does I+Med do?
I+Med is a pharmaceutical contract development and manufacturing organization (CDMO) that helps pharmaceutical companies develop and commercialize drug-delivery innovations using its proprietary ADAPTEK controlled-release technology platform, which combines patented nanohydrogels, active coatings for biomedical implants, and nanocarriers for vehiculization of active ingredients. In parallel, the company manufactures and sells its own portfolio of medical devices across five therapeutic areas — Traumatology, Aesthetics (including hyaluronic-acid injectables), Ophthalmology (viscoelastics and eye drops), Dermatology, and Veterinary — and offers custom R&D services (I+D a la carta) to clients requiring tailored vehiculization and molecule-delivery solutions.
Is I+Med a public or private company?
I+Med is a private company. It is classified as management employee owned and is currently operating.
When was I+Med founded?
I+Med was founded in 2014. It employs 11 to 50 people.
Where is I+Med based?
I+Med is headquartered in Álava, Spain, in the Europe region.
How does I+Med make money?
Four revenue lines are on record. Contract Development & Manufacturing (CDMO) is the primary driver. The others are own Product Portfolio, custom R&D Services (I+D a la carta) and technology Licensing / Co-development.
Who are I+Med's main competitors?
Emerging players on record are Lifepharma (Lifecare Biomedical), Nanoform Finland and Midatech Pharma. Broad incumbents are Recipharm, Evonik Health Care, Catalent, CordenPharma, Lonza and Rentschler Biopharma. Biana Med (formerly Bioiberica) is listed as a regional player.
Does I+Med have an API?
No public API is recorded for I+Med.
What industry is I+Med in?
I+Med's product category is Pharmaceutical Contract Development & Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.